Key Facts
| Invested since | 2021 |
| Based in | Baden-Württemberg |
About the company
WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is based on the fact that many cancer cells predominantly produce their energy through a high rate of glycolysis followed by lactic acid fermentation even in the presence of abundant oxygen. Using this mechanism for the treatment of cancer turns out to be very difficult, as interventions targeted at the sugar metabolism also cause harm to healthy cells. The approach WMT is using offers an improved therapeutic window as opposed to classical cancer medicines.
Do you want to
know more about this company?
WMT in the news
More startups from Life Sciences
Carelane is a health tech startup focused on addressing the inefficiencies in clinical trials by integrating multiple essential functions into a single, streamlined system, thereby digitizing study protocols and processes. …
To the complete profileof Carelane
Exit
Capical is the world leading company for contact-free ECG-measurement via capacitive electrodes. The main application areas are drivers state monitoring for the automotive industry and contact-free cardiac monitoring solutions for …
To the complete profileof Capical
TQ Therapeutics GmbH (Martinsried, Germany) is a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies. The company’s mission is to develop a transformative cell processing …
To the complete profileof TQ Therapeutics
Exit
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
To the complete profileof ChromoTek
DNTOX GmbH was founded in March 2022 as a spin-off from the IUF – Leibniz Institute for Environmental Medicine Research and is based on the longstanding research work of Professor …
To the complete profileof DNTOX
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility …
To the complete profileof Tacalyx
Exit
m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated …
To the complete profileof m2p-labs
Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary …
To the complete profileof mbiomics
Exit
lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family …
To the complete profileof Lino Biotech
Reactive Robotics is a leading healthcare startup dedicated to developing innovative technologies and solutions for the healthcare industry. The company is on a mission to revolutionize healthcare by integrating technology …
To the complete profileof Reactive Robotics
PraxisEins is a state-supported practice network with the aim of solving the impending GP care vacuum. In order to avert the structural undersupply in large parts of the country, the …
To the complete profileof PraxisEins
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
To the complete profileof Synendos Therapeuthics